IP Library Granted Patent US 11,802,284
Granted Patent B2
US 11,802,284 · App. 16/918,520 · Granted Oct 31, 2023

Medicine for treating cancer and method for treating cancer

Inventor: Kanako Niimori (Kumamoto, JP)
Assignees: NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY; TOKYO INSTITUTE OF TECHNOLOGY
C12N15/1135A61K31/713A61K45/00A61K48/00A61P35/00C07K16/18C07K16/30A61K2039/505C12N2310/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,802,284
App. No.
16/918,520
Granted
Oct 31, 2023
Kind
B2
Abstract

An object of the present invention is to reveal a role of a stem cell control factor including Matrin-3 in cancer exhibiting neural differentiation including small cell lung cancer, and develop a medicine useful for treating cancer and the like based on the role. Among cancers having the cancer stem cell controlling mechanism, in cancer exhibiting the differentiation potency, the peculiar balance where both of expression of a stem cell maintenance factor and expression of a differentiation promoting factor are higher as compared with normal cells is retained. Additionally, in undifferentiated cancer, the peculiar balance where expression of a stem cell maintenance factor is higher as compared with normal cells is retained. In cancer in which the cancer stem cell controlling mechanism exists, these peculiar balances of a stem cell control factor different from the balance of normal cells exist. In the medicine for treating cancer and the method for treating cancer of the present invention, proliferativeness of cancer is suppressed by breaking down this balance of a stem cell control factor.

Claims (5)

1. A method for suppressing the proliferation of small cell lung cancer cells, comprising introducing a siRNA or shRNA to the small cell lung cancer cells to suppress expression of a stem cell control factor, wherein the stem cell control factor is Matrin-3 or INI1, and wherein

the siRNA to Matrin-3 has the sequences of SEQ ID NO:1 and SEQ ID NO:2; SEQ ID NO:3 and SEQ ID NO:4; or SEQ ID NO: 5 and SEQ ID NO:6;

the shRNA to Matrin-3 has a sequence of any one of SEQ ID NO: 7 to 10, and

the siRNA to INI1 has the sequences of SEQ ID NO: 11 and SEQ ID NO: 12; SEQ ID NO: 13 and SEQ ID NO: 14; or SEQ ID NO: 15 and SEQ ID NO: 16.

2. A method for suppressing the neural differentiation of small cell lung cancer cells, comprising introducing a siRNA to INI1 to the small cell lung cancer cells to suppress expression of INI1, wherein the siRNA to INI1 has the sequences of SEQ ID NO: 11 and SEQ ID NO: 12; SEQ ID NO: 13 and SEQ ID NO: 14; or SEQ ID NO: 15 and SEQ ID NO: 16.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 10, 2025
From: INSTITUTE OF SCIENCE TOKYO
To: NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY
Reel/Frame 072213/0136 →
CHANGE OF NAME Recorded May 22, 2025
From: TOKYO INSTITUTE OF TECHNOLOGY
To: INSTITUTE OF SCIENCE TOKYO
Reel/Frame 071346/0912 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 1, 2020
From: NIIMORI, KANAKO
To: NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY; TOKYO INSTITUTE OF TECHNOLOGY
Reel/Frame 053102/0906 →
Priority Claims (1)
JP 2015-128139 · Jun 25, 2015 · national
Continuity (2)
Continuation 15739617
Related Publication 20200339995A1 · Oct 29, 2020